Biocytogen Holdings, a global biotechnology company driving drug discovery with innovative technologies, today announced it has entered into a global licensing agreement for antibody molecules with BeiGene, a global innovator in oncology treatment.
BeiGene has previously obtained the authorization to use Biocytogen’s RenMice® fully human antibody platform. Based on the good cooperation that has been established, the two parties have further expanded their cooperation to the field of antibody molecule licensing, which represents the continued deepening of their cooperation.
“BeiGene is a global leader in drug development, and we are pleased to enter into this strategic collaboration with them,” said Dr. Yuelei Shen, Chairman and CEO of Biocytogen. “The multiple antibody molecules licensed this time are derived from Biocytogen’s independently developed RenMice® fully human antibody discovery platform, which fully demonstrates our ability to empower partners and accelerate the development of innovative drugs. We look forward to these highly promising antibody molecules being able to advance to the clinical stage as soon as possible and bring innovative treatment options to patients around the world.”
Under the terms of the agreement, BeiGene will pay Biocytogen an upfront payment and will also be entitled to receive development and regulatory milestone payments, commercialization milestone payments, and royalties based on net sales.
About Biocytogen
Biocytogen (stock code: 02315.HK) is an international biotech company that is driven by innovative technology to develop new drugs and is committed to becoming the global source of new drugs. Based on the underlying gene editing technology, Biocytogen has independently developed the RenMice® (RenMab®, RenLite®, RenNano®, RenTCR-mimic®) platform for the discovery of fully human therapeutic monoclonal antibodies, bi/multi-specific antibodies, bispecific ADCs, nanobodies and TCR-like antibodies. Biocytogen is conducting large-scale drug development for more than 1,000 potentially druggable targets (the “Thousand Mice, Ten Thousand AntibodiesTM” project) and has established a library of more than 1 million fully human antibody sequences for global collaboration. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development/licensing/transfer agreements, and has reached more than 50 target projects with companies including several MNCs for RenMice® platform licensing and development cooperation, and has also reached external licensing cooperation for multiple clinical-stage antibody molecules. The company’s sub-brand BioMice® provides thousands of gene-edited animals and cell models, including target humanized mice, and provides preclinical pharmacology and gene editing services to customers around the world. Biocytogen is headquartered in Beijing and has branches in China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco, San Diego) and Heidelberg, Germany. For more information, please visit the official website https://www.biocytogen.com.cn/ .
About BeiGene
BeiGene is a global oncology innovation company registered in Switzerland, focusing on developing innovative anti-cancer drugs for cancer patients around the world. Through a rich product portfolio in hematology and solid tumors, as well as strong independent research and development capabilities and external strategic cooperation, we continue to accelerate the development of a diverse and innovative drug research and development product line, and are committed to comprehensively improving drug accessibility and affordability for more patients around the world. We have a team of more than 11,000 people on six continents. For more information, please visit www.beigene.com.cn or follow the WeChat public account of “BeiGene
